1. Milne C-P. Exploring the frontiers of law and science: FDAMA’s pediatric studies incentive. Food Drug Law J. 2002;57:491–517.
2. Kaitin KI, ed. Pediatric Study Costs Increased 8-Fold Since 2000 as Complexity Level Grew. Boston, MA: Tufts Impact Report; March/April 2007. Louis Lasagna Library, Tufts CSDD, Boston, MA; rachel.stanton@tufts.edu.
3. Kaitin KI, ed. Pediatric Regulatory Science, Clinical Trial Networks Hold Promise for Studies. Boston, MA: Tufts Impact Report; November/December 2016. Louis Lasagna Library, Tufts CSDD, Boston, MA; rachel.stanton@tufts.edu.
4. Wang J, Avant D, Green D, et al. A survey of neonatal pharmacokinetic and pharmacodynamics studies in pediatric drug development. Clin Pharmacol Ther. 2015;98:328–335.
5. Laughon MM, Avant D, Tripathi N, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168:130–136.